Prolargin Shows Early Promise as PAH Biomarker

Prolargin Shows Early Promise as PAH Biomarker

282744

Prolargin Shows Early Promise as PAH Biomarker

The prolargin protein may serve as a biomarker for pulmonary arterial hypertension (PAH), allowing for earlier diagnosis and differentiating among different types of pulmonary hypertension (PH), according to a recent study. The study, “Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension,” was published in the journal ESC Heart Failure. PAH can cause right heart failure, but non-specific symptoms such as shortness of breath (dyspnea) and fatigue can complicate obtaining a timely diagnosis. In…

You must be logged in to read/download the full post.